Status:
UNKNOWN
Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy
Lead Sponsor:
Amsterdam UMC, location VUmc
Collaborating Sponsors:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Medical Center Haaglanden
Conditions:
Epilepsy
Glioma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to investigate the correlation of SV2A expression in surgically removed tumour and tumour-surrounding tissue of glioma patients suffering from epilepsy with their clinical...
Detailed Description
Levetiracetam is a relatively novel anti-epileptic drug (AED), which has proven to be effective and well tolerated in many glioma patients with otherwise pharmacoresistant epilepsy. Moreover, levetira...
Eligibility Criteria
Inclusion
- age \> 18 years
- suffering from partial seizures, with or without secondary generalisation
- must have undergone surgery for their newly diagnosed or recurrent glioma not more than 42 days previously
- treated with levetiracetam
- histologically proven astrocytoma grade II or III, oligodendroglioma grade II or III, oligoastrocytoma grade II or III, or glioblastoma multiforme according to the World Health Organisation (WHO) classification of tumours affecting the central nervous system
- written informed consent
Exclusion
- Women who are pregnant or lactating
- Patients who do not have a basic proficiency of the Dutch language,or are unable to communicate adequately will also be excluded.
Key Trial Info
Start Date :
April 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00454935
Start Date
April 1 2007
End Date
October 1 2008
Last Update
June 9 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VU University Medical Center
Amsterdam, Amsterdam, Netherlands, 1081 HV